|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Clinical performance of bonded amalgam restorations at 42 months显示文摘 | Browning WD Johnson WW Gregory PN | 2000 | J Am Dent Assoc2000，131，5： | 1 |
| 2 | In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone resistant member of the familyEnterobacteriaceae and nonfermeuters显示文摘 | Fass RJ Gregory WW D Amato RF | 1990 | Antimicrob Agents che mother1990，34，： | 1 |
| 3 | In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriacear=e and nonfemeuters显示文摘 | Fass RJ Gregory WW D'Amato RF | 1990 | Antimicrob Agents Chemother1990，34，： | 1 |
| 4 | In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family ecterobacteriaceae and nonfermenters显示文摘 | Fass RJ Gregory WW D'amato RF | 1990 | Antimicrob Agents Chemother1990，34，11： | 1 |
| 5 | Recombinant human bone morphogenetic protein-7 induces healing in a canine long-bone segmental defect model 显示文摘 | Stephen DC Gregory CB Michael WW | 1994 | Clim Orthop1994，301，： | 1 |
| 6 | In vitro activities of cefoperazone and sulbactam singly and in combination against cefoperazone-resistant members of the family Enterobacteriaceae and nonfermeuters 显示文摘 | Fass RJ Gregory WW D'Amato RF | 1990 | Antimicrob Agents Chemother1990，34，： | 1 |
| 7 | Gene editing of CCR5 in autologous CD4 T cells ofpersons infected with HIV 显示文摘 | Tebas P Stein D Tang WW Frank I Wang SQ Lee G Spratt SK Surosky RT Giedlin MA Nichol G HolmesMC Gregory PD Ando DG Kalos M Collman RG Binder-Scholl G Plesa G Hwang WT Levine BL JuneCH | 2014 | N Engl J Med2014，370，10： | 1 |
| 8 | Reduction of postoperative pain: a double-blind, randomized clinical trial 显示文摘 | Browning WD Johnson WW Gregory PN | 1997 | J Am Dent As- soc1997，128，12： | 1 |
| 9 | In vitro activities of cefoperazone and sulbactam singly and in combination against ce- foperazone-resistant members of the family ecterobacteriaeeae and nonfermenters显示文摘 | Fass RJ Gregory WW Damato RF | 1990 | Antimicrob Agents Chemother1990，34，11： | 1 |
| 10 | In vitro activities of cefoperazone and sulbactam opera-zone and sulbactam singly and in combination against cefoperazone -resistant members of the family Enterobacteriaceae and nonfermeuters显示文摘 | Fass PJ Gregory WW D'Amato RF | 1990 | Antimicrob Agents chemother1990，34，： | 1 |
| 11 | Reduction of postoperative pain: A double-blind, randomized clinical trial 显示文摘 | Browning WD Johnson WW Gregory PN | 1997 | JADA1997，128，： | 1 |
| 12 | Analysis of the effects of donor and recipient hepatitis C infection on kidney transplant outcomes in the United States显示文摘BACKGROUND As Hepatitis C virus infection(HCV+)rates in kidney donors and transplant recipients rise,direct-acting antivirals(DAA)may affect outcomes.AIM To analyze the effects of HCV+in donors,recipients,or both,on deceased-donor(DD)kidney transplantation(KT)outcomes,and the impact of DAAs on those effects.METHODS The Organ Procurement and Transplantation Network data of adult first solitary DD-KT recipients 1994-2019 were allocated into four groups by donor and recipient HCV+status.We performed patient survival(PS)and death-censored graft survival(DCGS)pairwise comparisons after propensity score matching to assess the effects of HCV+in donors and/or recipients,stratifying our study by DAA era to evaluate potential effect modification.RESULTS Pre-DAA,for HCV+recipients,receiving an HCV+kidney was associated with 1.28-fold higher mortality(HR 1.151.281.42)and 1.22-fold higher death-censored graft failure(HR 1.081.221.39)compared to receiving an HCV-kidney and the absolute risk difference was 3.3%(95%CI:1.8%-4.7%)for PS and 3.1%(95%CI:1.2%-5%)for DCGS at 3 years.The HCV dual-infection(donor plus recipient)group had worse PS(0.56-fold)and DCGS(0.71-fold)than the dual-uninfected.Donor HCV+derived worse post-transplant outcomes than recipient HCV+(PS 0.36-fold,DCGS 0.34-fold).In the DAA era,the risk associated with HCV+in donors and/or recipients was no longer statistically significant,except for impaired PS in the dual-infected vs dual-uninfected(0.43-fold).CONCLUSION Prior to DAA introduction,donor HCV+negatively influenced kidney transplant outcomes in all recipients,while recipient infection only relatively impaired outcomes for uninfected donors.These adverse effects disappeared with the introduction of DAA. | Qing Yuan Shanjuan Hong Gregory Leya Eve Roth Georgios Tsoulfas WW Williams Joren C Madsen Nahel Elias | 2023 | World Journal of Transplantation2023，13，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员